Comparative Pharmacology
Head-to-head clinical analysis: ALBENDAZOLE versus MINTEZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENDAZOLE versus MINTEZOL.
ALBENDAZOLE vs MINTEZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Thiabendazole inhibits the mitochondrial fumarate reductase system in susceptible helminths, disrupting energy metabolism.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
50 mg/kg/day orally in 2-3 divided doses, maximum 3 g/day, for 2-3 days.
None Documented
None Documented
Clinical Note
moderateAlbendazole + Digoxin
"Albendazole may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlbendazole + Digitoxin
"Albendazole may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlbendazole + Deslanoside
"Albendazole may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAlbendazole + Acetyldigitoxin
"Albendazole may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Terminal elimination half-life: 2-8 hours (mean 4 hours). Hepatic impairment prolongs; dose adjustment recommended.
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Renal: 90% within 24 hours (5% unchanged, 85% as metabolites). Fecal: <10%.
Category D/X
Category C
Anthelmintic
Anthelmintic